News >

FDA Approves Lenvatinib/Pembrolizumab Combo for Advanced Endometrial Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Sep 17, 2019

The FDA has granted an accelerated approval to the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and who have disease progression following prior systemic therapy but are ineligible for curative surgery or radiation.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication